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Interventional Cardiology
DES Associated With Reduced Mortality and Subsequent MIs
Long-term outcomes with drug-eluting stents (DES) are addressed in 2 articles anda commentary in this issue of the Journal. Kelbæk and colleagues report 3-year
outcomes from the SCANDSTENT trial, which randomized subjects with complex
lesions to sirolimus-eluting stents (SES) or bare-metal stents (BMS). Major adverse
cardiac event rates were 3 times higher with BMS, driven mostly by repeat revascular-
izations; there was a statistically significant reduction in myocardial infarction (MI)
with SES. Groeneveld and colleagues used a Medicare database to develop a
propensity-matched cohort of up to 150,000 elderly patients who received either a
BMS or DES. Those who received DES had an adjusted mortality hazard ratio of 0.83.
The commentary by Anderson suggests that these reports show that DES not only
reduce restenosis, but may also improve mortality and lower the future risk of MI.
See pages 2011, 2017, and 2025. See figure.
Page 2031
Acute Coronary Syndromes
Early and Late Benefits of Prasugrel Compared With Clopidogrel
Prasugrel is a novel P2Y12 receptor inhibitor that was compared with clopidogrel inthe TRITON–TIMI 38 study of acute coronary syndrome patients undergoing
percutaneous coronary intervention. This report uses landmark analysis, with a day 3
cutpoint, to separate events that could be attributed to the loading dose (periprocedural
events) and the maintenance dose (events during long-term follow-up). Prasugrel
significantly reduced ischemic events during both periods. Bleeding was similar to
clopidogrel during the first 3 days, but was significantly higher during the maintenance
phase. These results suggest that further studies should focus on the safety of lowering
the maintenance dose of prasugrel, especially in patients at high risk for bleeding
complications. See page 2028. See figure.
Erectile Dysfunction
and Cardiac Disease
ED is a Strong Predictor of Adverse Cardiac Events in Diabetics
Two articles in this issue studied outcomes in diabetic males with or withouterectile dysfunction (ED). In 2,306 Chinese subjects with diabetes, 27% had ED
at baseline. These patients were twice as likely to experience a cardiac event, an excess
risk that remained significant after multivariate adjustment. Similarly, in nearly 300
Italian subjects with diabetes and coronary artery disease, the adjusted risk for major
adverse coronary events was 2.1 in those with ED. These 2 studies confirm that ED is
a potent risk marker for cardiovascular events in diabetics. See pages 2040, 2045,
and 2051.
(continued) A-24Heart Rhythm Disorders
Atrial Microvascular Dysfunction May Predispose to AF
Some recent evidence, including findings of fibrosis and loss of muscle mass in theatria, suggest that atrial ischemia may precipitate atrial fibrillation (AF). Skalidis
and colleagues report that fractional flow reserve in the left atrial circumflex branch
artery is lower in subjects with a history of AF than in control subjects. These results
provide more evidence that microvascular dysfunction and atrial ischemia may con-
tribute to the pathophysiology of AF. See page 2053.
